We are thrilled to share that the STAMPEDE2 trial has randomised its first patient into Comparison S at the Royal Marsden Hospital Chelsea, on Tuesday 9th July. Comparison S aims to explore the potential benefits of adding Stereotactic Ablative Body Radiotherapy (SABR) to standard of care for men whose prostate cancer has spread to a limited number of body areas. A big thank ...